Back to News
Market Impact: 0.25
Shield Therapeutics Reports Q3 Revenue Of $11.5 Mln; U.S. ACCRUFeR Sales Rise 5%; Stock Down
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Shield Therapeutics reported Q3 2026 Group net revenue of $11.5 million, versus ACCRUFeR net revenue of $13.1 million in the year-ago quarter. The reported figures indicate a lower year-over-year comparison, but the article provides no expectations or explanation for the change.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
STX-0.40
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge